Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 129Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Mucosta

02 8Mucosta Ophthalmic Suspension

PharmaCompass

01

Brand Name : Mucosta

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 72

2019 Revenue in Millions : 82

Growth (%) : -12

blank

02

Brand Name : Mucosta Ophthalmic Suspension

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta Ophthalmic Suspension

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Ophthalmology

Currency : USD

2020 Revenue in Millions : 49

2019 Revenue in Millions : 50

Growth (%) : -2

blank

03

Brand Name : Mucosta

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2021 Revenue in Millions : 72

2020 Revenue in Millions : 69

Growth (%) : 12

blank

04

Brand Name : Mucosta Ophthalmic Suspension

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta Ophthalmic Suspension

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Ophthalmology

Currency : USD

2021 Revenue in Millions : 46

2020 Revenue in Millions : 47

Growth (%) : 4

blank

05

Brand Name : Mucosta Ophthalmic Suspension

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta Ophthalmic Suspension

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Ophthalmology

Currency : USD

2022 Revenue in Millions : 42

2021 Revenue in Millions : 46

Growth (%) : -9

blank

06

Brand Name : Mucosta

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2022 Revenue in Millions : 78

2021 Revenue in Millions : 72

Growth (%) : 9

blank

07

Brand Name : Mucosta

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2023 Revenue in Millions : 71

2022 Revenue in Millions : 78

Growth (%) : 3

blank

08

Brand Name : Mucosta Ophthalmic Suspension

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta Ophthalmic Suspension

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Ophthalmology

Currency : USD

2023 Revenue in Millions : 29

2022 Revenue in Millions : 42

Growth (%) : -20

blank

09

Brand Name : Mucosta

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2016 Revenue in Millions : 117

2015 Revenue in Millions : 144

Growth (%) : -19

blank

10

Brand Name : Mucosta Ophthalmic Suspension

Rebamipide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Mucosta Ophthalmic Suspension

arrow
2024 ACI Convention
Not Confirmed

Rebamipide

Main Therapeutic Indication : Ophthalmology

Currency : USD

2016 Revenue in Millions : 45

2015 Revenue in Millions : 45

Growth (%) : 0

blank